Stock

Corcept Therapeutics Incorporated

CORT

Medical - Pharmaceuticals · Healthcare

Also trades as: 0I3Q.L GBP 1.18 (-1.83%)

Price

$118.54

-1.06 (-0.89%)

Market Cap

$12.81B

Exchange

NASDAQ

Winston Score

Winston is curious

A decent business — some strong pillars, some weaker.

Data as of Oct 9, 2026 · filings through Jun 30, 2026

§How the score breaks down

Quality

Good

17/30

Growth

Mixed

6/20

Cash Flow

Exceptional

9/10

Stability

Exceptional

10/10

Valuation

Good

5/10

Ownership

Good

10/15

Dividends

Not counted

n/a

57 of 95 counted points = Winston Score 60. Pillars marked n/a do not apply to this company and are left out of the total.

Track this stock — start free trial

Share count falling — buybacks

−4.7% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 126.0M (2021) → 120.0M (2025)

§Winston Score History

The full picture

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.

Politician Trades

5 trades / 12mo

3 Congressional buys and 2 sells on CORT in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+31.7% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+21.2% YoY

YoY Growth Rate

Steady EPS growth

R&D Spend

$255M/ year

→ Flat (+3% vs prior year)

33.5% of revenue

1.9x the sector average (18%)

Steady R&D investment year-over-year

Insider Activity

16.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$308M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Revenue accelerating

Corcept Therapeutics Incorporated grew revenue 32% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

98.4%

Premium pricing power — 98.4% gross margin

Profit after running costs

Operating Margin

16.1%

Healthy — 16.1% operating margin

Return on the money invested

ROCE

0.9%

Weak — 0.9% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+16.0%

Fast-growing sales (+16.0% YoY)

Profit growth

EPS YoY

-58.7%

Earnings shrinking (-58.7% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

200%

Turns 200% of profit into real cash

Spare cash per sale

FCF Margin

12.9%

Converts sales into free cash efficiently (12.9%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

100.00x

—

Comfortably covers interest (100.0x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

228.0x

Expensive — P/E 228.0

P/E over 35. The market is pricing in heavy, sustained growth.

Cheaper or dearer next year

P/E vs Forward

+212.4

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (228.0 → 15.5)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial